Non-alcoholic steatohepatitis (NASH) is a chronic liver disease characterized by excessive triglyceride accumulation in the liver accompanied by inflammation, cell stress and apoptosis. It is the tipping point to the lifethreatening stages of non-alcoholic fatty liver disease (NAFLD). Despite the high prevalence of NASH, up to five percent of the global population, there are currently no approved drugs to treat this disease. Animal models, mostly based on specific diets and genetic modifications, are often employed in anti-NASH drug development. However, due to interspecies differences and artificial pathogenic conditions, they do not represent the human situation accurately and are inadequate for testing the efficacy and safety of potential new drugs. Human-based in vitro models provide a more legitimate representation of the human NASH pathophysiology and can be used to investigate the dysregulation of cellular functions associated with the disease. Also in silico methodologies and pathway-based approaches using human datasets, may contribute to a more accurate representation of NASH, thereby facilitating the quest for new anti-NASH drugs.
patients suffering from simple steatosis progress to NASH, it still affects 3 to 5 percent of the world population [5] .
NASH represents the hepatic manifestation of the metabolic syndrome, which explains its concomitant risk factors such as obesity, insulin resistance, diabetes mellitus type 2, dyslipidemia and hypertension [6] . However, multiple research projects have failed to elucidate the exact molecular mechanisms driving the accumulation of lipid droplets in the cytoplasm of hepatocytes and the accompanying liver inflammation [7] .
To date, no drugs have been approved to cure NASH [8] . NAFLD drug development focuses on targeting metabolic risk factors and tackling causes of the metabolic syndrome [9] . Vitamin E and thiazolidinediones, peroxisome proliferator-activated receptor (PPAR)-γ agonists, are off-label treatments for NASH and show low efficacy [10] . The major obstacles in the development of high-potential anti-NASH drug candidates are the identification of possible drug targets and the lack of adequate NASH models. The most stringent costs of the drug development process are associated with early basic research, i.e. identifying new druggable targets [11, 12] . The fact that to date no humanrelevant predictive models exist to study NASH, fosters this expensive process. Yet, the market value for NASH treatment was estimated at $0.8 billion for 2015 and is believed to increase to circa $15 billion by 2025 [10] .
Several animal models have been developed to study steatosis and NASH. NASH in vivo models can be divided into genetically modified animals, diet-induced animals or their combination [13, 14] . However, due to its heterogeneous pathology, most animal models do not represent the human situation accurately [14] . The interspecies differences associated with their use form a major drawback. In addition, the pathogenic stimuli used to induce NAFLD in animals are artificial and often not related to the human pathogenesis [15] . Moreover, the use of experimental animals is increasingly being discouraged due to ethical concerns [16] . For these reasons, human-based, non-animal approaches have been gaining ground during the last decades. The data obtained using these systems are directly relevant to the human situation and are in general not associated with ethical concerns. Additionally, the simplicity of some human-relevant disease models allows a clear and independent focus on specific mechanistic aspects of the disease.
Several human-based in vitro systems have been established to investigate steatosis and NASH. Hepatoma-derived cell lines, mainly HepG2, Huh7 and HepaRG are most widely used [17, 18] . These cell lines, however, lack population diversity and exhibit an abnormal genotype because of their cancerous background. In addition, they poorly exhibit liver-specific metabolic competence, which forms a major drawback. This is in contrast to primary human hepatocytes, which are considered the gold standard for hepatic in vitro modeling. Yet, primary human hepatocytes also lose their xenobiotic biotransformation enzymatic activity in culture and their availability for research purposes is limited due to intensified organ transplantation programs [19] . Immortalized human hepatocytes could address the shortage of primary human cells, but concerns related to genotypic and phenotypic drift in immortalized cells still exist [17] . Primary human stellate cells and cell lines and primary human Kupffer cells have also been used to study the inflammatory and fibrogenic insults contributing to the progression of NASH. Co-culturing these non-parenchymal cells with hepatic cells mimicks in a more realistic way the human liver environment. To date, only a limited number of attempts have been documented in this field [16, 20] . The major advancement in cell biology of the last decade is, however, the introduction of human stem cells as a potential unlimited source of hepatic cells reflecting population diversity. Yet, only a few studies related to NAFLD using human stem cells have been published [21, 22] .
Overall, the inclusion of all features of NAFLD and the metabolic syndrome within an in vitro model remains challenging. To bridge the gap between simplified in vitro models and the human situation, systems biology approaches are being conceived to unveil the causes that drive NAFLD. Although only a dozen of studies have been published so far, a breakthrough in the identification of biomarkers and drug targets using those approaches is imminent.
This review discusses the processes and pathological pathways that encompass the molecular markers, currently under investigation as potential anti-NASH druggable targets. Where appropriate, available human-based, alternative approaches are alluded.
Strategies for the development of in vitro NASH models
Two decades ago, Day et al. described the 'two hit' hypothesis as an explanation for the pathogenesis of NASH. In their hypothesis, steatosis develops first and sensitizes the liver for the second hit, which involves oxidative stress, mitochondrial dysfunction and pro-inflammatory stimuli [23] . This hypothesis is now obsolete and a 'multiple hit' hypothesis has been introduced that better reflects the pathogenesis of NASH as today [1] . The most important mechanisms involved in NASH are summarized in Fig. 2 . To prevent potential mechanistic ambiguity between animals and humans, exclusively human data is reported in this review.
One of the major aspects in the pathogenesis of NASH is the dysregulation of nuclear receptors in hepatocytes. These transcription factors regulate a series of mechanisms implicated in liver (patho) physiology such as lipogenesis and β-oxidation (Fig. 2) . Table 1 summarizes their involvement in NAFLD and shows the utility of human cell models in their investigation.
NASH is considered to represent the hepatic manifestation of the metabolic syndrome, which includes a range of factors that cannot be featured within a single in vitro model [24] . To adequately mimic the complex pathology of this disease, in vivo conditions need to be carefully selected and translated into in vitro setups. Several single-celltype approaches that mimic 'metabolic syndrome conditions' have been investigated, as well as genetic modifications related to NAFLD. Yet, an unicellular hepatic model is unlikely to be able to provide all the characteristics of the disease such as the involvement of stellate cells, Kupffer cells and circulating immune cells upon hepatic injury [25, 26] . To date, only limited success has been obtained when establishing complex co-cultures that mimic the hepatic environment [27, 28] . Therefore, to maintain the simplicity of in vitro systems, factors secreted by non-parenchymal cells that play a role in NASH, can be added to the cell culture medium instead of complex co-cultures. This permits the development of single cell systems in which the soluble microenvironment of NASH is imitated. Simultaneous co-culture is, however, still necessary if the role of cell-cell contact between distinct cell types is investigated [26, 29, 30] . Due to increasing evidence of the involvement of the gut-liver axis in NASH, specific attention should also be paid to the gut microbiota and interstinal barrier integrity. Structural and practical limitations of in vitro systems hinder such experimental setups. Nonetheless, clear-cut strategies such as including endotoxins in the cell culture media, can be followed [31] .
The use of human stem cells in hepatic disease modelling can overcome several drawbacks of primary and hepatoma-derived hepatic cell models. Induced pluripotent stem cells (iPSC), adult stem cells (ASC) and embryonic stem cells (ESC), are perceived as an unlimited source of hepatic cells [21, 22, 32] . Continuous advances in hepatic differentiation strategies, allows the generation of hepatic cells with increasing metabolic capacities, which was previously a major shortcoming of stem cell-derived hepatocytes [33] . Moreover, stem cell- derived hepatic systems are suitable for long-term exposure studies, representing chronic liver disease. The use of stem cells obtained from donors carrying certain genetic polymorphisms related to NAFLD could also facilitate the development of more relevant disease models [34] [35] [36] . Fig. 3 recapitulates the most important factors to consider when developing a predictive NAFLD in vitro system.
Although, no optimal in vitro NASH model has been documented yet, several studies report the applicability of in vitro hepatic systems to study NASH. The efficacy of several potential anti-NASH molecules was already investigated using these cell-based systems [18, 22, [37] [38] [39] [40] [41] .
Studies reporting the biological processes and cellular mechanisms involved in NASH and their investigation using in vitro systems are summarized in Table 2 .
Biological processes in NASH and their investigation in vitro

De novo lipogenesis and lipid accumulation
The first key enzyme in de novo lipogenesis, but indirectly also in β-oxidation, is acetyl-coenzyme-A carboxylase 1 (ACC1), which converts acetyl-coenzyme-A into malonyl-CoA. Malonyl-CoA on its turn inhibits Several factors, mainly related to inflammatory and lipotoxic processes, play a role in the onset of NASH. Triggers associated to the metabolic syndrome, such as increased insulin, glucose and free fatty acids levels, activate transcription factors that control de novo lipogenesis and mitochondrial function. Dysregulation of β-oxidation leads to the generation of ROS and ER-stress, which then causes cell damage and cell death. In addition, the intracellular triglyceride pool decreases, resulting in a lower lipotoxic buffer capacity of the cell. Although, protective mechanisms such as the unfolded protein response and autophagy are switched on, they are not able to maintain cellular homeostasis. Also stimuli provided by non-parenchymal liver cells as well as stimuli from extra-hepatic tissues play a role in the onset of NASH. Kupffer cells, get stimulated through PAMPs derived from the gut and DAMPs from the hepatocyte, leading to stellate cell activation. As a result, the stellate cells convert into myofibroblasts that produce extracellular matrix, which marks the next stage of NASH, namely fibrosis. Furthermore, evidence points to a crucial role of the genetic background in the NAFLD pathology, which may intervene in the steatotic, inflammatory and fibrotic pathways.
[ Figure abbreviations : ACC1, acetyl-coenzyme A carboxylase 1; AP-1, activator protein 1; APOB, apolipoprotein B; CCL, C-C chemokine ligand; CCR, C-C chemokine receptor; CD36, cluster of differentiation 36; ChREBP, carbohydrate-responsive element-binding protein; CK-18, cytokeratin 18; CPT-1, carnitine palmitoyltransferase 1; DAMPs, danger-associated molecular patterns; ECM, extracellular matrix; ER, endoplasmic reticulum; FABP, fatty acid-binding protein; FAE, fatty acid elongase; FAS, fatty acid synthase; FATP-2/5, fatty acid transport protein-2/5; FFA, free fatty acids; FXR, farnesoid X receptor; HDL, high-density lipoprotein; IL, interleukin; LPS, lipopolysaccharide; LXR-α, liver X receptor α; MBOAT7, membrane bound O-acyltransferase domain containing 7; MPR, misfolded protein response; NLRP3, nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3; NF-κB, nuclear factor-kappa B; PAMPs, pathogenassociated molecular patterns; PNPLA3, patatin-like phospholipase domain-containing protein 3; PPAR, peroxisome proliferator-activated receptor; PXR, pregnane X receptor; ROS, reactive oxygen species; SCD1, stearoyl-coenzyme A desaturase 1; SREBP-1c, sterol regulatory element-binding protein; TGF-β, transforming growth factor-β; TLR, toll-like receptor; TM6SF2, transmembrane 6 superfamily 2; TNF-α, tumor necrosis factor-α; UPR, unfolded protein response; VLDL, very low-density lipoprotein].
carnitine palmitoyltransferase (CPT)-1, which is involved in the transport of fatty acids into mitochondria, thereby affecting β-oxidation [42] . ACC1 expression is decreased in advanced NASH patients compared to simple steatosis subjects [43] . This enzyme is the first druggable target in the de novo lipogenesis pathway [44] . The next enzyme in line is fatty acid synthase (FAS) that converts malonyl-CoA into palmitic acid, a 16-carbon saturated fatty acid. When compared to healthy individuals, FAS is upregulated at both the mRNA and protein levels in simple steatosis subjects, whilst on the other hand, NASH patients show an impaired FAS function. Hence, triglyceride formation is perceived as a protective buffer for toxic free fatty acids [43, 45] . In addition, ACC and FAS expression in NASH patients also correlates inversely with the fibrosis stage [43] . The formed saturated fatty acids are further converted into mono-unsaturated fatty acids [46] by stearoyl-CoA desaturase (SCD)1, which is upregulated in steatosis patients [47] .
De novo lipogenesis is mainly regulated transcriptionally, but can be targeted on different levels [48] . Antagonism of the nuclear liver X receptor (LXR) is thought to inhibit the action of different downstream transcription factors (e.g. sterol regulatory element-binding protein (SREBP-1c), carbohydrate-responsive element-binding protein (ChREBP)) and the enzymes ACC, FAS and SCD1. This has been described in an adverse outcome pathway (AOP) of steatosis and is illustrated in Fig. 2 [49] [50] [51] [52] . The expression of LXR is increased in NAFLD • PHH [65] • HepG2 [65] • • PHH [65] • HepG2 [65, 99] • iPSC, ESC [22] • hSKP-HPC [21] PPAR-β/δ β -oxidation Fatty acids Steatosis: = [43, 82] NASH: = [43, 82] • PHH [39] PPAR-γ Adipocyte differentiation Fatty acids Steatosis: = [43, 82] NASH: = [43, 82] • HepG2 [65] [ In order to better recapitulate the human liver environment and pathophysiology, three-dimensional co-cultures and the use of cells with the appropriate genetic background should be implemented when modelling NAFLD in vitro. Furthermore, different pathogenic processes need to be translated towards the in vitro setting to reflect the multiple hits driving human NAFLD. although alterations in expression are not clear for its counterpart, the farnesoid X receptor (FXR) ( Table 1 ) [53, 54] . Nevertheless, FXR seems to be an attractive drug target for NAFLD and multiple compounds that target this nuclear receptor are under development [9, 37, 55] . Experiments with both primary human hepatocytes as well as with hepatic cell lines and stem cell-derived hepatocyte-like cells, could successfully recapitulate the molecular alterations observed in vivo. Oleic acid and palmitic acid, respectively an unsaturated and saturated fatty acid, are most often used to induce intracellular lipid accumulation. Using primary hepatocytes and carcinoma-derived cell lines, in which different oleic acid:palmitic acid ratios were investigated, it was oberved that saturated fatty acids are more toxic and harmful than unsaturated fatty acids and that the latter can only be used to simulate non-malignant chronic steatosis [56] [57] [58] [59] [60] . Kostrzewski et al. developed a dynamic three-dimensional primary human hepatocyte-based NAFLD system in which oleic acid and palmitic acid were used to induce steatosis and a NASH-like state. In this system, pioglitazone and metformin, two drugs used for the treatment of diabetes mellitus type 2, reduced steatosis by different mechanisms. However, they did not have a significant effect on the inflammatory state induced by palmitic acid [38] . Also human immortalized hepatocytes and hepatic cell lines (HepG2, Huh7, HepaRG) exposed to fatty acids show NAFLD-specific changes in lipogenic gene expression [20, 61, 62] . The utility of in vitro models for anti-NAFLD drug testing was also shown using oleic acid and palmitic acid loaded Huh7 and HepG2 cells exposed to exendin-4, a glucagon-like peptide-1 (GLP-1) agonist, where it induced an antisteatotic response [63] .
Although applicable for modelling NAFLD [64] , fatty acids are not responsible for triggering de novo lipogenesis. Therefore, approaches applying supra-physiologic (≥ 100 nM) insulin and glucose concentrations, reflecting insulin resistance and hyperglycemia in vivo, have also been investigated. Indeed, lipid accumulation has been observed in primary human hepatocytes exposed to high glucose and insulin concentrations. In concordance with the accumulated lipids, primary human hepatocytes show an upregulation of SREBP-1c, ACC, FAS and SCD1, which is in line with human data from steatosis patients [65, 66] .
Taking the abovementioned lipogenic factors, Feaver et al. established a dynamic in vitro NASH model by co-culturing primary human hepatocytes with hepatic stellate cells and macrophages. This system was exposed to human-relevant concentrations of insulin (6,9 nM), glucose (25 mM) and fatty acids (palmitic acid 45 μM and oleic acid 65 μM) and showed strong similarity with human liver samples from NASH patients at the lipidome and transcriptome levels. As a proof-of-principle, this in vitro system was exposed to obeticholic acid (OCA), a FXR agonist under investigation as an anti-NASH compound in a phase III clinical trial. After exposure to OCA, the intracellular lipid content was reduced by 25% and the lipidome returned to a healthy profile with concomitant decrease in the secretion of pro-inflammatory and fibrotic factors [27] . Elafibranor, a PPAR-α/δ agonist, currently under evaluation in a phase III clinical, was later tested in this system and was found to decrease steatosis to a larger extend than OCA. Furthermore, elafibranor intervened in pathways associated with more advanced NASH, indicating the usefulness of this sophisticated in vitro system for anti-NASH drug testing [39] . Studies using HepG2 cells and primary human hepatocytes provided additional evidence for a link between FXR and PPAR-α [67] .
Although the major causes of NAFLD are related to the metabolic syndrome and obesity, commonly used drugs can also induce intrahepatic lipid accumulation, which has been clearly demonstrated in vitro. HepG2 cells accumulated lipids upon exposure to tamoxifen. Increased expression of SREBP-1c and its downstream genes ACC, FAS and SCD could be demonstrated, showing that this cell line is useful for the identification of compounds that induce fatty liver [68] . Drug-induced steatosis was also investigated using HepaRG ells, in which exposure to tetracycline and amiodarone led to the intracellular accumulation of lipid vesicles [69] . Furthermore, also hepatocyte-like cells derived from multipotent ASC showed an upregulation of de novo lipogenic genes (FAS, SCD and DGAT2) upon exposure to sodium valproate, a well-known steatotic compound [70] . The observed gene expression modulation was in line with data obtained from patients suffering from steatosis [21] . In addition, it was recently reported that these ASC are also able to detect drug-induced phospholipidosis [71] . More specialized three-dimensional cultures remain, however, mainly unexplored as a possible source for the assessment of NAFLD-inducing substances. Yet, a three-dimensional culture consisting of primary human hepatocytes showed already its competence to evaluate potential hepatotoxicity of a range of on-the-market drugs [72] . It would be valuable to concomitantly screen for intracellularly accumulated lipids in this model.
Fatty acid intake and triglyceride transport
Extra-hepatic fatty acids, originating from lipolysis of adipose tissue or obtained through the diet, are delivered to the liver by the bloodstream. As illustrated in Fig. 1 , four different transporter types transfer these fatty acids from the plasma to the hepatocyte, namely caveolins, fatty acid-binding proteins (FABP), fatty acid transport proteins (FATP) and fatty acid translocase (FAT) [13] . FAT or cluster of differentiation (CD)36 is the most important fatty acid transporter in the onset of NAFLD as it mediates the uptake of long chain fatty acids into hepatocytes [73] . Besides the internalization of fatty acids, hepatocytes also secrete lipids. Secretion of accumulated or newly synthesized triglycerides from the hepatocytes into the bloodstream is mediated by very low-density lipoprotein (VLDL) [74] . Apolipoprotein B (ApoB)-100, a building block of VLDL, ensures vesicle hydrophilicity, allowing lipid transport into the blood [74] . A significant upregulation of CD36 at the gene and protein levels has been observed for hepatocytes isolated from liver tissue from NASH patients with insulin resistance, hyperinsulinemia and steatosis [75] . In accordance, it has been shown in vitro that palmitic acid increases CD36 expression in HepG2 cells [65] . CD36 was also upregulated in hSKP-HPC exposed to sodium valproate, suggesting an increased drug-induced import of fatty acids into the cell. In addition, a down-regulation of ApoB was also noticed, implying that less triglycerides are secreted through VLDLs, which contributes as well to the intracellular lipid accumulation [21] . These observations are also in agreement with data obtained from samples of NASH patients [74, 76] .
β-oxidation
β-oxidation is a multistep process in the mitochondria by which fatty acids are broken down for the production of ATP. How the dysregulated β-oxidation contributes to the pathogenesis of NAFLD is not clear. Increased β-oxidation as well as the opposite situation have been observed in NAFLD. A decline in the degradation of fatty acids does, however, result in hepatic steatosis [77] . In vitro, increased β-oxidation has been observed in primary human hepatocytes in co-culture with stellate cells and macrophages in a lipotoxic medium [27] . García-Ruiz et al. investigated the mitochondrial oxidative phosphorylation system in HepG2 cells upon exposure to saturated fatty acids. In this cell model, saturated fatty acids induce oxidative stress [78] , indicating mitochondrial lipotoxicity as a results of excessive lipid load. Accordingly, HepG2-derived C3A cells exposed to a mixture of lactate, pyruvate, octanoate and ammonia, mimicking an excess in energy intake, also show dysregulated mitochondrial respiration [79] .
Fatty acids are transported into the mitochondrion by CPT-1, which is located in the outer mitochondrial membrane [80] . The expression of CPT-1 is downregulated in NAFLD livers, possibly due to increased malonyl-CoA levels [81] . The nuclear receptor PPAR-α is a known regulator of CPT-1A and its expression is also decreased in NASH patients (Table 1 and Fig. 2) [82] . Recently, Graffmann et al. established two NAFLD in vitro models originating from iPSC and ESC differentiated towards hepatocyte-like cells. In these models, oleic acid was used to induce intracellular lipid accumulation and led to alterations in glucose-and lipid metabolism-related gene expression, which was in line with data obtained from human steatosis biopsies. Agonism and antagonism of PPAR-α by fenofibrate and GW6471, respectively, revealed the involvement of this nuclear receptor in the onset of steatosis in hepatocyte-like cells [22] . Other PPAR subtype agonists can activate β-oxidation as well. As such, in HepaRG, a series of different PPAR agonists were able to reduce oleic acid-induced lipid accumulation [18] . Although these compounds do not act solely on β-oxidation due to the multi-regulatory nature of PPARs, these in vitro experiments do confirm the relevance of targeting different PPAR-subtypes in NAFLD [83] .
Cholesterol metabolism
Free cholesterol molecules exert lipotoxic effects on hepatocytes and play a role in the progression from steatosis towards NASH. Free cholesterol is higher in NASH patients' liver tissue, but not in subjects with simple steatosis. In a cohort of 14 NASH patients, upregulation of SREBP-2, a major transcriptional regulator of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA), the rate-limiting enzyme in de novo cholesterol synthesis, was observed compared to the simple steatosis group [84] . Furthermore, cholesterol crystals were found in the livers of NASH patients [85] . According to recent findings, fructose intake might also play a pivotal role in the cholesterol metabolism and subsequent progression of NAFLD [86] . In vitro experiments with Huh7 cells showed indeed higher cholesterol storage upon increasing fructose:glucose ratios [87] .
Although indications for altered cholesterol metabolism are present in NASH, a small trial with 16 NASH patients showed that 12 months treatment with simvastatin, a HMG-CoA inhibitor, does not improve serum aminotransferase levels, liver steatosis, fibrosis or inflammation [88] . Yet in vitro, simvastatin reduces the lipid content of oleic acidexposed HepG2 cells, therefore indicating a beneficial effect of statins on NAFLD [89] . This discrepancy needs further investigation, but might be due to the small cohort involved in the in vivo study. In contrast, rosuvastatin, belonging to the same drug class as simvastatin, was found to alleviate NASH after 12 months treatment, supporting the in vitro findings with simvastatin [90] .
Inflammation
Several non-specific (adipo)cytokines, chemokines and the nucleotide-binding domain leucine-rich-containing family, pyrin domaincontaining-3 (NLRP3) inflammasome are involved in the pathogenesis of NASH [24, 91] . The origin of hepatic inflammation in NASH is, however, unclear and finding the right targets for its treatment is difficult.
In vitro models can provide mechanistic insights on how direct simulation of inflammation and lipotoxicity contribute to NASH. Studies in which primary human hepatocyets were exposed to palmitic acid, show a transcriptional induction of C-C motif chemokine ligand (CCL)5 [92] and tumor necrosis factor (TNF)-α, indicating that free fatty acids can drive inflammation [65] . Observations like the former are relevant for defining new therapeutic targets. For example, cenicriviroc, a dual-C-C motif chemokine receptor (CCR)2/CCR5 antagonist, showed improvement of fibrosis and no worsening of NASH after one year of treatment in a phase IIb study [93] .
While most studies focus on hepatocytes, the adipose tissue also secretes a spectrum of important cytokines involved in NAFLD (Fig. 2) . High concentrations of interleukin (IL)-6 are known to be excreted by the adipose tissue of NASH patients. This anomaly decreases following weight loss of the patients [94] or after treatment with vitamin E [95] . The IL-6 concentration in serum and liver tissue correlates with the degree of inflammation and the rate of fibrosis [96] . This was also seen in the NASH co-culture of Feaver et al., where an increase in secretion of inflammatory cytokines, including IL-6, could be measured [27] . Using the carcinoma-derived Huh7 cell line, higher expressions of IL-6, IL-8 and TNF-α were observed upon exposure to saturated and unsaturated fatty acids [59] .
Adiponectin, an anti-inflammatory and antilipogenic adipokine exclusively produced by the adipose tissue, is decreased in NASH patients [97] . When human immortalized hepatocytes are exposed to insulin, they show a decreased adiponectin receptor (AdipoR) 2 expression, while TNF-α exposure induces the latter. Exposure to pioglitazone curbed the insulin-induced downregulation of AdipoR2, suggesting that PPAR-γ agonism ameliorates the harmful effects of hyperinsulinemia, among others, through this mechanism [98] . Regarding PPAR-α, it has been demonstrated that, using HepG2, the anti-inflammatory properties of PPAR-α agonism are exerted among others through inhibition of nuclear factor-kappa B (NF-κB) and activator protein 1 (AP-1) [99] .
Increasing evidence is available for the crucial role of inflammasomes in the pathogenesis of NASH. The NLRP3 inflammasome is the most extensively studied [100] . After inflammasome assembly, caspase-1 activation leads to proteolytic activation of the pro-inflammatory cytokines IL1β and IL18 [101] . The high free cholesterol levels that have been observed in NASH patients can cause cholesterol crystallization in hepatic tissue, possibly activating NLRP3 [102] . Intrestingly, HepG2 cells exposed to palmitic acid also accumulate cholesterol and show a concomitant increase in NLRP3 and IL-1β protein levels [103] , indicating the potential role of the diet in inflammasome activation.
Many other (anti-)inflammatory cytokines are thought to be involved in steatosis and NASH and therefore further research is necessary to unravel this complex, but important aspect of NAFLD. Mechanistic in vitro studies can definitely contribute to the acquisition of this relevant information.
Cell stress, cell death and autophagy
Apoptosis in hepatocytes is distinctive between patients suffering from NASH or simple steatosis. Higher caspase-3 and caspase-7 activities as well as an increase in cytokeratin-18 fragments, an apoptotic marker, have been measured [104] . This was also observed in the coculture of Feaver et al. [27, 105] . Furthermore, it was also shown that palmitic acid and cholesterol exposure induces apoptosis in HepG2 cells [106, 107] .
The increased apoptosis rate in NASH patients creates a concomitant rise in hepatic oxidative stress [108] . In cultures of Huh7 cells, increased reactive oxygen species (ROS) concentrations have been observed in response to exposure to saturated and unsaturated fatty acids [59] . Upon stress conditions, misfolded and unfolded proteins accumulate intracellulary in an attempt to attain homeostasis. However, ERstress and accumulation of unfolded proteins can result in subsequent cell death [109] . Although saturated fatty acids, such as palmitic acid, are more toxic to hepatocytes than unsaturated ones (e.g. oleic acid), the latter is toxic for stellate cells [110] . When HepG2 cells were exposed to palmitic acid, an increase in ER-stress markers, namely CCAAT/enhancer-binding protein homologous protein (CHOP) and X-box binding protein-1s was observed [103] . Yet, other genes (activating transcription factor 6, DNA damage inducible transcript 3 and heat shock protein family A member 5) involved in ER-stress, were downregulated upon longer exposure periods [65] . This suggests that other protective mechanisms may be implicated. As such, Huh7 cells exposed to palmitic acid for 8 h exhibit an unfolded protein response and increased autophagy. When exposed for 24 h, an induction of ER-stress associated with a decrease in autophagy and cell death was noticed. CHOP silencing and treatment with rapamycin, an inducer of autophagy, was demonstrated to improve these events and reduce apoptosis [111] . The latter study was partly confirmed by the discovery of protective autophagy mechanisms in primary human hepatocytes exposed to palmitic acid [112] . Impaired autophagy has previously been associated with the progression from steatosis to NASH [113] . Although its role in lipid storage disorders is not completely elucidated yet, it is considered a potential therapeutic target against NASH [114, 115] .
It should be noted that the previous studies using in vitro approaches recapitulate in much shorter time periods specific mechanisms of the human NASH pathophysiology, which normally take several years to develop. Therfore, in vitro models are extremely valuable for rapid assessment of the effectiveness of new drugs. For example, rosiglitazone treatment of SK-Hep-1 cells exposed to fatty acids and TNF-α, led to a decrease in cytotoxicity [40] .
Aditionally, primary human hepatocytes exposed to palmitic, oleic and elaidic acid showed a reduction in lipid content and ER-stress with concomitant induction of autophagy when exposed to GLP-1 agonist exendin-4 [116] . As such, GLP-1 agonists (e.g. liraglutatde), are being tested for the treatment of NASH [24] .
Gut-liver axis
NAFLD patients show increased hepatic endotoxin levels that are possibly derived from the gut [1] . Pathogen-associeted molecular patterns (PAMPs), e.g. lipopolysaccharide (LPS) from Gram-negative bacteria, can contribute to insulin resistance and interact with hepatic Tolllike receptors, inducing an inflammatory response (Fig. 2) [117] . Primary human hepatocytes exposed to LPS show an upregulation of IL-6, IL-1β, IL-10 and signal transducer and activator of transcription 5, which is reduced upon insulin treatment [118] , providing evidence for a PAMPinsulin interplay. In addition, LX-2 stellate cells exposed to LPS exhibit an upregulation of IL-6, IL-1β, TNF-α, transforming growth factor (TGF)-β and collagen type (COL) 6 transcription, showing its inflammatory inducing properties [31, 119] .
Elevated serum ethanol values attributed to changes in the gut microbiome have also been reported in NASH patients [120] . Increased expression of alcohol-metabolizing enzymes, like cytochrome P450 (Cyp)2E1, has been measured in NAFLD patients and was comparable with the expression in alcoholic fatty liver. This supports the hypothesis that endogenous alcohol fulfills a role in the pathogenesis of NAFLD [121] .
Debatable, exposure of primary human hepatocytes to both palmitate and ethanol induces Cyp2E1 expression [122] . When these cells are cultured using a three-dimensional fluidic system, they show even higher Cyp2E1 mRNA levels [38] . This was also obsereved in HepaRG cells exposed to steraric acid [66] .
Genetic variation
Particular genetic polymorphisms portray an advanced propensity to develop NAFLD. The patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 variant correlates not only with the progression from simple steatosis towards NASH, but also with the severity of steatosis and fibrosis in these patients. Transmembrane 6 superfamily 2 (TM6SF2) rs58542926 and membrane bound O-acyltransferase domain containing 7 (MBOAT7) rs641738 probably also relate to the disease progression [34] [35] [36] 123, 124] . Of these three variants, PNPLA3 and TM6SF2 have been investigated in vitro.
PNPLA3
The PNPLA3 rs738409 variant is related to increased hepatic fat content, inflammation and possibly stellate cell activation [123, 125, 126] . In humans, PNPLA3 expression is highest in the liver, whereas in mice it is higher in adipose tissue. This makes it difficult to correlate rodent studies on PNPLA3 to the human situation [127] . HepG2 cells naturally carry the PNPLA3 rs738409 variant on both alleles and therefore hold an adequate genetic background for the investigation of NAFLD development in vitro [128] . Wildtype Huh7 cells exposed to fatty acids exhibit a post-translationally regulated increase in PNPLA3 protein amount, without changes at the mRNA level [127] .
Interestingly, using Huh7 cells and human immortalized hepatocytes, it was demonstrated that the PNPLA3 rs738409 mutant impairs triglyceride hydrolysis and induces triglyceride accumulation [129, 130] . The exact mechanistic explanation for the influence of the different PNPLA3 alleles on the onset of NAFLD remains, however, unclear. PNPLA3 rs738409 might also be involved in the inflammatory and fibrotic component of NASH. LX-2 and primary hepatic stellate cells overexpressing the PNPLA3 rs738409 variant, show a stronger expression of CCL-2, CCL-5, granulocyte-macrophage colony-stimulating factor and IL-8, suggesting a regulatory role in inflammation. In addition, primary human stellate cells knocked-down for PNPLA3, show lower alpha smooth muscle actin (α-SMA) expression, indicating that PNPLA3 is involved in fibrogenesis as well [131] .
TM6SF2
The TM6SF2 gene is a master regulator of the metabolic syndrome. Decreased VLDL export has been reported in NASH patients carrying TM6SF2 rs58542926, promoting steatosis but at the same time decreasing plaque formation by lowering triglyceride export into the blood stream [132] . In vitro, knockdown and transient silencing of TM6SF2 in Huh7 cells, results in lipids with a lower polyunsaturated fatty acid (PUFA) content. This corresponds to the observations in NAFLD patients carrying TM6SF2 rs58542926, in which less PUFAs are present in hepatic lipids [133, 134] .
Fibrosis
Fibrosis is one of the strongest predictors of advancing NASH [135] . The major regulator of hepatic fibrosis is TGF-β1, a pro-inflammatory and pro-fibrogenic pleiotropic cytokine that activates stellate cells to produce extracellular matrix proteins [136] . Monocytes, Kupffer cells and stellate cells are the principal producers of TGFβ1 [137] . The serum levels of this cytokine are higher in NASH patients compared to simple steatosis subjects [138] .
The LX-2 stellate cell line is often employed to study hepatic fibrogenesis and to test anti-fibrotics [139] . Upregulated mRNA expression of pro-fibrogenic genes (α-SMA, TGF-β1 and tissue inhibitor of metalloproteinase) was observed in these cells when exposed to oleate and palmitate [140] . In addition, primary human stellate cells co-cultured in a lipotoxic medium with primary human hepatocytes and human Kupffer cells, show an increase in α-SMA expression, reflecting the in vivo situation [27] . Wobser et al. exposed hepatic stellate cells to the conditioned medium of primary human hepatocytes that were previously exposed to palmitate. This led to the activation and proliferation of the stellate cells, which could also better resist apoptosis [58] . Based hereon, it was concluded that direct cell-cell contact is not necessary for stellate cell activation. This is, however, in contrast to findings done in co-cultures of the Huh7 cell line with LX-2 stellate cells, either in a simultaneous set up, in which the cells were in contact with each other or using transwells, whereby the two cell types were separated. Exposure to palmitic acid and oleic acid induced vesicular steatosis in each culturing condition [28] . Yet, only the simultaneous co-culture showed an increased α-SMA expression. The transwell system showed a decrease in the profibrotic gene [59] . This led to the conclusion that extracellular matrix formation depends on direct cellcell contact [28] .
Pathway-based approaches
Systems biology, in which different omics technologies are used, can unravel complex biological networks and may help to elucidate the pathogenesis of NASH. Hereby, in silico approaches composed of computational and mathematical methods integrate existing (human) datasets. Martel et al. have shown that merging transcriptomics, proteomics and lipidomics data allows the identification of main pathogenic mechanisms involved in NAFLD [141] . More profound analysis was done by Mardinoglu et al. by constructing iHepatocytes2322, a genome-scale metabolic model based on proteomic and transcriptomic data from NASH patients. Analyzing transcriptomic data from NAFLD patients, revealed that serine deficiency was related to NASH [142] . Recently, a genome-scale metabolomics study used stable isotope infusion to analyze individual lipoprotein fluxes of subjects suffering from hepatic steatosis, and found NAD + and glutathione deficiencies. Decreased glycine and serine levels were also present as a likely cause of insufficient gluthatione content. The possible benefit from serine supplementation was confirmed by administration of serine to subjects suffering from hepatic steatosis. Despite the fact that only six persons were included in the study, all of them showed decreased hepatic steatosis [143] . Metabolomic analysis of the plasma of NAFLD subjects also showed a shift in compounds associated with glutathione. Lower glutathione/glutathione disulfide ratios further supported these findings [144, 145] . Connecting transcriptomics data from NAFLD patients to metabolite levels through the livers' splanchnic bed has allowed the development of a genome-scale model. Herein, excessive lipid load reduced the metabolic adaptability. It also induced mitochondrial activity, glyceroneogenesis and a shift to glycerol instead of lactate as substrate for gluconeogenesis [146] .
Systems biology approaches based on in vitro models are scarce, but can nevertheless also provide valuable information. For example, the implementation of a systems biology approach with transcriptomics and proteomics data from the human hepatoblastoma C3A cell line exposed to steatotic inducers showed intracellular lipid accumulation, ROS and mitochondrial impairment and an upregulation of fibrinogens related to NAFLD. Therefore, this in vitro application could predict supplementary risk factors such as cardiovascular disease, which is the most important co-morbidity of NAFLD [147] . Following a holistic methodology, Jozefczuk et al. combined patient-derived, in vitro and in silico experimental data to study the etiology of steatosis, unraveling key mechanisms that are possibly involved in the onset of NAFLD [148] . This type of studies, which solely rely on the holistic analysis of human data, are essential for a better understanding of the mechansims that drive NAFLD.
Conclusion: roadmap for pre-clinical human-based NAFLD research
NASH is a complex disorder and its heterogeneity among patients makes the establishment of defined endpoints to evaluate new models to study this disease difficult. Modern techniques, including transcriptomics, proteomics and metabolomics, become more reliable and may therefore provide valuable insights in the mechanistic background of NAFLD [141, 147, 148] .
Most of the currently used methods in the pre-clinical testing of anti-NASH drugs are, however, based on a reductional analysis of available clinical data. Systems biology approaches can address this problem by analyzing data of established cohorts of patients with a specific NASH etiology. Furthermore, since not all patients exhibit the same risk factors, appropriate in vitro systems can be fine-tuned to better reflect the individual pathology, using available datasets obtained from patients suffering from NASH. This could be done using human-based computational systems, which will further strengthen their predictive capacity and make application in the preclinical stage of drug development a reality (Fig. 4) .
NASH in vitro modelling could not only benefit from co-cultures and three-dimensional setups, but also from mechanistic approaches to address the complex pathology. As such, metabolic disturbances due to (single) genes, enzymes or pathways identified through systems analysis in specific patient groups, can be modelled in vitro [142, 143] .
The established in vitro models that reflect the individual human diversities are already today a valuable tool. The application of twodimensional in vitro models in drug screening is practical, economical and therefore of high value, but also three-dimensional NAFLD models have been established, with or without an integrated microfluidic system. The fluidic co-culture NASH model, based on primary human hepatocytes with hepatic stellate cells and macrophages, tested by Feaver et al., is up to now considered as being the best representation of the human situation. However, the supply of high-quality primary human hepatocytes is limited and until this problem is resolved, the utilization of such a systems in drug screening applications is unfeasible. Human stem cell-based approaches might be useful to cover not only the lack of primary human cells but also the inter -individual and -population differences. These cells can be obtained in high numbers and have the potential to differentiate towards all the cell types needed to build a suitable NASH-model. Since the genetic background plays a pivotal role in disease progression, a pre-screening for the 'suitable' genetic NASH-background should be the approach to follow.
Elafibranor and OCA, targeting PPAR-α/δ and FXR, respectively, are currently the most promising drugs in the pipeline for the treatment of NASH [24] . These compounds have been successfully tested using in vitro steatosis/NASH models, providing evidence for the applicability of Clinical data should be the starting point for the development of adequate in vitro systems. Omics technology can provide a data pool, which forms the basis for the design of more predictive in vitro human-based screening systems. These systems can be applied to investigate new therapeutic targets, to evaluate the mechanisms of action of new chemical entities or to perform safety assessment of anti-NASH new chemical entities. Consequently, the discontinuation of potential drugs during the drug development process due to lack of efficacy and safety constraints will be less likely, reducing costs and improving market approval.
in vitro models in anti-NASH research and drug development [27, 37, 39] . As the economic burden of drug development relies mainly on the early drop-out of new chemical entitities [11] , the development of highly predictive human-based in vitro models along with humanbased (clinical) systems analysis may represent a more cost-effective, reliable and predictive methodology for anti-NASH drug development.
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